



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Group Art Unit: 1646

James Lee et al.

Examiner: John D. Ulm

Application No.: 10/666,689

Confirmation No: 2217

Filed: September 19, 2003

CUSTOMER NO: 09157

For:

HUMAN PF4A RECEPTORS, (as

amended)

Express Mail No. EV384508739 US Mail Date: April 14, 2006

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

[] 37 CFR §1.97(b)

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR§1.491, or
- before the mailing of the first Office action on the merits; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

[X] 37 CFR §1.97(c)

• by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the

application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

[] 37 CFR §1.97(d)

 after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) and a statement as specified in 37 CFR §1.97(e), as checked below.

[If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.]

- [] 37 CFR §1.97(e) Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- [] 37 CFR §1.704(d) Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- [X] The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) and/or publication(s) is set forth on the attached revised Form PTO-1449. Copies of the items listed on the PTO-1449 form are supplied herewith, except for United States patent(s) and United States patent application publication(s) and other documents that are marked with an asterisk (*) in the attached PTO-1449 form. Copies of United States patents and United States patent application publications will not be supplied unless requested by the Office [37 CFR §1.98(a)(2)(ii)]. See Final Rule 1287 OG (October 12, 2004).

A concise explanation of relevance of the items listed on PTO-1449 is:

- [X] not given
- [] given for each listed item

Application No.: 10/666,689 Filing Date: September 19, 2003

Page 3

- [] given for only non-English language listed item(s) [Required]
- [] in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

GENENTECH, IN

Date: April 14, 2006

Craig G. Svoboda

Reg. No. 39,044

Telephone No. (650) 225-1489

FORM	PTO-1	449 Old S. Dept. of Commerce	Atty Docket No.	Serial No.
		Patent and Trademark Office	P0706P2C2D2C1	10/666,689
/ · • • • • • • • • • • • • • • • • • •			Applicant	
LIST	OF DIS	SCLOSURES CITED BY APPLICANT (APR 1 4 2006	Lee et al.	
(U	lse sev	eral sheets if necessary)	Filing Date	Group
		A Handard C	. 19 Sep 2003	1646
OTHER DISCLOSURES (including Author, Title, Date, Pertinent Pages, etc.)				
		Luster, Andrew D. et al., "Immune cell migration in inflammation targets" Nature Immunology 6(12):1182-1190 (Dec 2005)		
	87	Miller, Michael D., Ph.D. et al., "Biology and Biochemistry of the Chemokines: A Family of Chemotactic and Inflammatory Cytokines" <u>Critical Reviews in Immunology</u> 12(1,2):17-46 (1992)		
	88	abroe, I. et al., "Chemokines, innate and adaptive immunity, and respiratory disease" <u>European</u> espiratory Journal 19:350-355 (2002)		
,	89	Schmutz, Caroline et al., "Chemokine receptors in the rheumatoid synovium: upregulation of CXCR5" Arthritis Research & Therapy 7(2):R217-R229 (Dec 16, 2004)		
	Stoeckle, Mark Y. et al., "Two Burgeoning Families of Platelet Factor 4-Related Proteins: Mediators of the Inflammatory Response" The New Biologist 2(4 (April)):313-323 (1990)			
		i.e.	in the second	
		·		
	٠		•	· .
			·	
			· · · · · · · · · · · · · · · · · · ·	
				
<u>.</u>				· ·
Examine			ate Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant				